Travere Therapeutics
TVTX
320 hedge funds and large institutions have $5.98B invested in Travere Therapeutics in 2026 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 123 increasing their positions, 85 reducing their positions, and 28 closing their positions.
218% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 28
175% more funds holding in top 10
Funds holding in top 10: 4 → 11 (+7)
99% more capital invested
Capital invested by funds: $3.01B → $5.98B (+$2.97B)
55% more call options, than puts
Call options by funds: $77.8M | Put options by funds: $50.1M
45% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 85
23% more funds holding
Funds holding: 261 → 320 (+59)
4.23% more ownership
Funds ownership: 109.9% → 114.13% (+4.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$143M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$70.6M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$51.2M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$46.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$172M |
| 2 |
AC
Armistice Capital
New York
|
-$147M |
| 3 |
State Street
Boston,
Massachusetts
|
-$31.2M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$31.1M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$22.2M |
TVTX Hedge Fund Activity: Q2 2026 in Review
320 of the 8,331 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2026, worth a combined $5.98B — up 99% from $3.01B a quarter earlier.
Buyers outnumbered sellers: 89 funds opened new TVTX positions and 28 closed out — a net gain of 61 holders — while 123 added to existing stakes and 85 trimmed.
The largest buyer was Bank of America, adding an estimated $143M. The largest seller was Fidelity Investments, cutting an estimated $172M.
- 320 institutional investors held Travere Therapeutics (TVTX) as of Q2 2026, up from 261 in Q1 2026.
- Funds reported $5.98B of Travere Therapeutics stock for Q2 2026, up 99% quarter-over-quarter.
- 89 funds opened new Travere Therapeutics positions in Q2 2026 and 28 closed out, a net change of +61 holders.
- The largest Travere Therapeutics buyer in Q2 2026 was Bank of America, an estimated $143M added.
- The largest Travere Therapeutics seller in Q2 2026 was Fidelity Investments, an estimated $172M sold.
Based on aggregated 13F filings for Q2 2026.